Commitment to Action

Reaching Women with a New Method of Contraception

Commitment by

Evofem Llc

In 2013, Evofem committed to make its new non-hormonal contraceptive gel, Amphora, available and affordable to women in the developing world, upon successful completion of trials and regulatory approval. More than 200 million women in the developing world lack access to modern contraceptives and those who do have access do not always have choice. While prospective pharmaceutical company acquirers will likely be most interested in Amphora's potential in US and European markets, Evofem intends to negotiate with possible acquirers to carve out rights to Amphora distribution in less developed countries in Africa, Latin America, and Asia. In conjunction with nonprofit supply chain specialists, like WomanCare Global, Evofem will seek to ensure that any acquisition of Amphora will contain a plan for large-scale access to Amphora in the developing world, in order to meet its social mission.

Share

Tabs

Overview
Summary

Commitment

Reaching Women with a New Method of Contraception

Launched

2013

Est. Duration

3 years

Estimated Total Value

$

Region

Northern America

Countries

Global

Commitment by

Evofem Llc

Partner(s) of the Commitment Maker(s)

WomanCare Global